Scarica l'app Stockscreener
48.82
1.43%
0.69
Dopo l'orario di chiusura:
49.00
0.18
+0.37%
Kiniksa Pharmaceuticals International Plc Borsa (KNSA) Ultime notizie
If You Invested $1,000 in Kiniksa Pharmaceuticals International, plc (KNSA) - Stock Titan
KNSA PE Ratio & Valuation, Is KNSA Overvalued - Intellectia AI
[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity - Stock Titan
Kiniksa (KNSA) CFO receives new options, RSUs and PSUs in 2026 award - Stock Titan
Kiniksa (NASDAQ: KNSA) CEO awarded options, RSUs and PSUs, covers tax - Stock Titan
Kiniksa (KNSA) CMO granted options, RSUs and PSUs in equity awards - Stock Titan
Kiniksa (KNSA) COO receives major equity awards and exercises RSUs - Stock Titan
Kiniksa (KNSA) CAO receives options, RSUs, PSUs and adds to shareholdings - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the Minervini Trend Template with High-Growth Momentum - ChartMill
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) stock price, news, quote and history - Yahoo Finance Singapore
KNSA Should I Buy - Intellectia AI
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year HighShould You Buy? - MarketBeat
Hennion & Walsh Asset Management Inc. Trims Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa's discounted P/S ratio reflects investor caution amid weak growth forecasts. Sentiment may not turn bullish unless the company delivers stronger-than-expected revenue growth. - moomoo.com
JPMorgan Chase & Co. Has $7.47 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Vanguard realignment leads to 0-share filing for Kiniksa (KNSA) - Stock Titan
SG Americas Securities LLC Has $22.33 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International PLC (KNSA) Trading 3.48% H - GuruFocus
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a High-Growth Momentum Setup - ChartMill
Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance - msn.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top GARP Investment - ChartMill
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Pullback - Yahoo Finance
Kiniksa Pharmaceuticals International, plc Q4 2025 earnings preview - MSN
Kiniksa Pharmaceuticals International PLC (KNSA) Stock Price Up 3.67% on Mar 16 - GuruFocus
Granahan Investment Management LLC Sells 27,421 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by ArrowMark Colorado Holdings LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Acquires 101,666 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
FMR LLC's Strategic Acquisition of Kiniksa Pharmaceuticals Shares - GuruFocus
Kiniksa (KNSA) CFO sells 36,722 shares after exercising options - Stock Titan
Kiniksa (NASDAQ: KNSA) insider sale notice lists 36,722 shares (Rule 144) - Stock Titan
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going - MSN
FMR LLC holds 10.6% of Kiniksa (KNSA) — 4.85M shares reported - Stock Titan
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again - MSN
Vanguard Group Inc. Trims Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and Bullish Chart Setup - ChartMill
Fisher Asset Management LLC Acquires 180,029 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals CMO Sells Shares Worth Nearly $1.8 Million - TradingView
Kiniksa Pharmaceuticals (KNSA) CMO sells 40K shares after option exercise - Stock Titan
How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility - simplywall.st
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Robust Growth Potential With 23% Upside - DirectorsTalk Interviews
Kiniksa (NASDAQ: KNSA) Rule 144 notice: 40,000-share cashless exercise - Stock Titan
KNSA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing - ChartMill
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility - Yahoo Finance
KNSA/N Stock Price and Chart — BIVA:KNSA/N - TradingView
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewswire
The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts - Benzinga
KNSA: Wells Fargo Raises Price Target and Maintains Overweight R - GuruFocus
KNSA: Wedbush Raises Price Target to $53, Maintains Outperform R - GuruFocus
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Compelling Value Investment - ChartMill
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Biopharma's Strong Growth Trajectory And 17.9% Upside Potential - DirectorsTalk Interviews
Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens - MSN
Beyond the Balance Sheet: What SWOT Reveals About Kiniksa Pharma - GuruFocus
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):